ANRO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Alto Neuroscience Inc (ANRO) is not a strong buy at this time for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. While the company has promising analyst coverage and innovative drug programs, the lack of significant financial growth, hedge fund selling trends, and absence of recent positive news or catalysts make it prudent to hold off on buying this stock right now.
The technical indicators show mixed signals. The MACD is positive and expanding, indicating bullish momentum. The RSI is neutral at 55.511, suggesting no overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading above its pivot level of 15.568 with resistance at 16.729 and support at 14.408. However, the recent price decline of -1.62% and the broader market downturn (S&P 500 down -1.54%) indicate caution.
Analyst BTIG initiated coverage with a Buy rating and a $27 price target, citing innovative biomarkers and near-term data readouts.
Bullish moving averages and positive MACD momentum.
Hedge funds are selling, with a 159.20% increase in selling activity over the last quarter.
Financials show no revenue growth and a worsening net income (-15.50% YoY) and EPS (-16.13% YoY).
No recent news or significant insider or congress trading activity.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$14.18 million (-15.50% YoY), and an EPS decline to -0.52 (-16.13% YoY). Gross margin remains at 0%. The financials indicate a lack of profitability and growth.
BTIG analyst Thomas Shrader initiated coverage with a Buy rating and a $27 price target, highlighting the company's innovative drug programs and near-term data readouts. However, no other analyst updates or revisions are noted.
